Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 29

1.

Interference with Protease-activated Receptor 1 Alleviates Neuronal Cell Death Induced by Lipopolysaccharide-Stimulated Microglial Cells through the PI3K/Akt Pathway.

Li Y, Yang W, Quinones-Hinojosa A, Wang B, Xu S, Zhu W, Yu F, Yuan S, Lu P.

Sci Rep. 2016 Dec 2;6:38247. doi: 10.1038/srep38247.

2.

Resveratrol suppresses NTHi-induced inflammation via up-regulation of the negative regulator MyD88 short.

Andrews CS, Matsuyama S, Lee BC, Li JD.

Sci Rep. 2016 Sep 28;6:34445. doi: 10.1038/srep34445.

3.

Cyclic nucleotide phosphodiesterase 1 and vascular aging.

Yan C.

Clin Sci (Lond). 2015 Dec;129(12):1077-81. doi: 10.1042/CS20150605.

4.

Identification of a cell-penetrating peptide domain from human beta-defensin 3 and characterization of its anti-inflammatory activity.

Lee JY, Suh JS, Kim JM, Kim JH, Park HJ, Park YJ, Chung CP.

Int J Nanomedicine. 2015 Aug 26;10:5423-34. doi: 10.2147/IJN.S90014.

5.

Vinpocetine inhibits Streptococcus pneumoniae-induced upregulation of mucin MUC5AC expression via induction of MKP-1 phosphatase in the pathogenesis of otitis media.

Lee JY, Komatsu K, Lee BC, Miyata M, O'Neill Bohn A, Xu H, Yan C, Li JD.

J Immunol. 2015 Jun 15;194(12):5990-8. doi: 10.4049/jimmunol.1401489.

6.

Shuang-huang-lian attenuates lipopolysaccharide-induced acute lung injury in mice involving anti-inflammatory and antioxidative activities.

Fang L, Gao Y, Liu F, Hou R, Cai RL, Qi Y.

Evid Based Complement Alternat Med. 2015;2015:283939. doi: 10.1155/2015/283939.

7.

Vinpocetine reduces carrageenan-induced inflammatory hyperalgesia in mice by inhibiting oxidative stress, cytokine production and NF-κB activation in the paw and spinal cord.

Ruiz-Miyazawa KW, Zarpelon AC, Pinho-Ribeiro FA, Pavão-de-Souza GF, Casagrande R, Verri WA Jr.

PLoS One. 2015 Mar 30;10(3):e0118942. doi: 10.1371/journal.pone.0118942.

8.

Inhibition of the NLRP3 inflammasome provides neuroprotection in rats following amygdala kindling-induced status epilepticus.

Meng XF, Tan L, Tan MS, Jiang T, Tan CC, Li MM, Wang HF, Yu JT.

J Neuroinflammation. 2014 Dec 17;11:212. doi: 10.1186/s12974-014-0212-5.

9.

Cyclic nucleotide phosphodiesterases: important signaling modulators and therapeutic targets.

Ahmad F, Murata T, Shimizu K, Degerman E, Maurice D, Manganiello V.

Oral Dis. 2015 Jan;21(1):e25-50. doi: 10.1111/odi.12275. Review.

10.

Vinpocetine inhibits amyloid-beta induced activation of NF-κB, NLRP3 inflammasome and cytokine production in retinal pigment epithelial cells.

Liu RT, Wang A, To E, Gao J, Cao S, Cui JZ, Matsubara JA.

Exp Eye Res. 2014 Oct;127:49-58. doi: 10.1016/j.exer.2014.07.003.

11.

Vinpocetine attenuates neointimal hyperplasia in diabetic rat carotid arteries after balloon injury.

Wang K, Wen L, Peng W, Li H, Zhuang J, Lu Y, Liu B, Li X, Li W, Xu Y.

PLoS One. 2014 May 12;9(5):e96894. doi: 10.1371/journal.pone.0096894.

12.

Inhibitory effects of vinpocetine on the progression of atherosclerosis are mediated by Akt/NF-κB dependent mechanisms in apoE-/- mice.

Zhuang J, Peng W, Li H, Lu Y, Wang K, Fan F, Li S, Xu Y.

PLoS One. 2013 Dec 9;8(12):e82509. doi: 10.1371/journal.pone.0082509.

13.

Clinical and molecular genetics of the phosphodiesterases (PDEs).

Azevedo MF, Faucz FR, Bimpaki E, Horvath A, Levy I, de Alexandre RB, Ahmad F, Manganiello V, Stratakis CA.

Endocr Rev. 2014 Apr;35(2):195-233. doi: 10.1210/er.2013-1053. Review.

15.

Vinpocetine attenuates lipid accumulation and atherosclerosis formation.

Cai Y, Li JD, Yan C.

Biochem Biophys Res Commun. 2013 May 10;434(3):439-43. doi: 10.1016/j.bbrc.2013.03.092.

16.

Inhibition of PDE4B suppresses inflammation by increasing expression of the deubiquitinase CYLD.

Komatsu K, Lee JY, Miyata M, Hyang Lim J, Jono H, Koga T, Xu H, Yan C, Kai H, Li JD.

Nat Commun. 2013;4:1684. doi: 10.1038/ncomms2674.

17.

Berberine ameliorates chronic kidney injury caused by atherosclerotic renovascular disease through the suppression of NFκB signaling pathway in rats.

Wan X, Chen X, Liu L, Zhao Y, Huang WJ, Zhang Q, Miao GG, Chen W, Xie HG, Cao CC.

PLoS One. 2013;8(3):e59794. doi: 10.1371/journal.pone.0059794.

18.

PDE5 Inhibitors as Potential Tools in the Treatment of Cystic Fibrosis.

Noel S, Dhooghe B, Leal T.

Front Pharmacol. 2012 Sep 18;3:167.

19.

Vinpocetine suppresses pathological vascular remodeling by inhibiting vascular smooth muscle cell proliferation and migration.

Cai Y, Knight WE, Guo S, Li JD, Knight PA, Yan C.

J Pharmacol Exp Ther. 2012 Nov;343(2):479-88. doi: 10.1124/jpet.112.195446.

20.

EVI1 acts as an inducible negative-feedback regulator of NF-κB by inhibiting p65 acetylation.

Xu X, Woo CH, Steere RR, Lee BC, Huang Y, Wu J, Pang J, Lim JH, Xu H, Zhang W, Konduru AS, Yan C, Cheeseman MT, Brown SD, Li JD.

J Immunol. 2012 Jun 15;188(12):6371-80. doi: 10.4049/jimmunol.1103527.

Supplemental Content

Support Center